Aliases:This biomarker is also known as:
- Monocyte chemoattractant protein 1,
- Monocyte chemotactic protein 1,
- chemokine (C-C motif) ligand 2,
- monocyte chemotactic and activating factor,
- C-C motif chemokine 2,
- monocyte chemoattractant protein-1,
- small-inducible cytokine A2,
- monocyte secretory protein JE,
- Small-inducible cytokine A2,
- small inducible cytokine A2 (monocyte chemotactic protein 1, homologous to mouse Sig-je),
- monocyte chemoattractant protein 1,
- Monocyte secretory protein JE,
- Monocyte chemotactic and activating factor,
- monocyte chemotactic protein 1,
- small inducible cytokine subfamily A (Cys-Cys), member 2,
CCL2, also known as MCP-1, is a member of the chemokine superfamily. Chemokines are a family of small cytokines. The four chemokine subfamilies are based on the arrangement of N-terminal cysteine residues of the mature peptide. CCL2 is a member of the CC subfamily, characterized by two adjacent cysteine residues. CCL2 is a chemotactic factor that attracts monocytes and basophils but not neutrophils or eosinophils. CCL2 has been implicated in the pathogenesis of diseases characterized by monocytic infiltrates, like psoriasis, rheumatoid arthritis or atherosclerosis. It binds to chemokine receptors CCR2 and CCR4.
There are no datasets associated with this biomarker.
The following organs have data associated with this biomarker…
|QA State:||Under Review|
No additional breast data available.
CCL2, also known as MCP-1, was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.
- Plasma biomarker profiles differ depending on breast cancer subtype but RANTES is consistently increased.
- Discovery and preliminary confirmation of novel early detection biomarkers for triple-negative breast cancer using preclinical plasma samples from the Women's Health Initiative observational study.
- Development and validation of sandwich ELISA microarrays with minimal assay interference.